Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Gazyva is the brand name for obinutuzumab, a monoclonal antibody given by intravenous infusion. It targets CD20 on B cells. It is used in certain treatment plans for chronic lymphocytic leukemia, follicular lymphoma, and active lupus nephritis in adults.
read more about gazyva ...Gazyva is combined with other medicines for previously untreated chronic lymphocytic leukemia. It is also used in specified treatment plans for follicular lymphoma, including disease that has returned after or resisted a rituximab-containing regimen. Adults with active lupus nephritis may receive it while continuing standard therapy.
Obinutuzumab binds to CD20, a protein on certain B cells. This helps the immune system eliminate those cells and reduces the B cells involved in the treated conditions. The treatment plan depends on whether Gazyva is being used for blood cancer or lupus nephritis.
A healthcare professional administers Gazyva as an infusion into a vein. The infusion schedule differs by condition and treatment phase. Medicines may be given beforehand to reduce infusion reactions, and staff monitor patients during treatment.
Infusion reactions, infections, and low blood cell counts can occur. Gazyva carries boxed warnings for hepatitis B reactivation and progressive multifocal leukoencephalopathy, a rare, serious brain infection. Patients are screened for hepatitis B before treatment and should promptly report new neurologic symptoms or signs of infection.
Gazyva is a CD20-directed antibody. It may be given alongside chemotherapy for certain blood cancers.
Yes. It is indicated for adults with active lupus nephritis who are receiving standard therapy.
Treatment can reactivate a prior hepatitis B infection. Screening helps the care team plan monitoring and treatment.
Yes. Staff monitor for reactions and may give medicines before the infusion to lower the risk.
FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis. Genentech. https://www.gene.com/media/press-releases/15085/2025-10-19/fda-approves-genentechs-gazyva-for-the-t. Date Accessed October 6, 2026.
GAZYVA- obinutuzumab injection, solution, concentrate. DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda. Date Accessed October 6, 2026.
Obinutuzumab. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/obinutuzumab. Date Accessed October 6, 2026.
Obinutuzumab (intravenous route) - Side effects & uses. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/obinutuzumab-intravenous-route/description/drg-20088520. Date Accessed October 6, 2026.
Obinutuzumab Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a614012.html. Date Accessed October 6, 2026.